March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Maculopexy: A New Treatment for Diffuse Diabetic Macular Edema
Author Affiliations & Notes
  • Robert E. Morris
    Retina Spec of Alabama, LLC, Birmingham, Alabama
  • Matthew H. Oltmanns
    Retina Spec of Alabama, LLC, Birmingham, Alabama
  • Gregory M. Lewis
    Retina Spec of Alabama, LLC, Birmingham, Alabama
  • Footnotes
    Commercial Relationships  Robert E. Morris, None; Matthew H. Oltmanns, None; Gregory M. Lewis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 350. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert E. Morris, Matthew H. Oltmanns, Gregory M. Lewis; Maculopexy: A New Treatment for Diffuse Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2012;53(14):350.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the safety and efficacy of maculopexy (the production of microscopic chorioretinal adhesions by grid laser treatment together with gas tamponade) combined with intravitreal triamcinolone acetate (combined assisted maculopexy, CAMP) to permanently increase retinal resistance to expansion as a new treatment for diffuse diabetic macular edema (DDME).

Methods: : Retrospective, consecutive case series of 10 eyes of 10 patients with DDME that did not have foveal ischemia, all treated by CAMP.

Results: : Visual acuity improved significantly (0.43 (20/54) to 0.26 (20/36) logMAR (Snellen), p=0.04) as did optical coherence tomography (OCT) central thickness (433 to 220 uM, p=0.0002). Mean length of follow-up was 43.6 months (range 8-72). Five patients (50%) had 2 or more Snellen lines of improvement, 2 had 1 line of improvement and 3 remained unchanged. Eight of 8 eyes (100%) with foveal cysts had resolution of the cysts with concave fovea at final follow-up.

Conclusions: : CAMP appears to be a safe and effective new treatment for DDME, a common and visually debilitating condition that has heretofore had no satisfactory treatment. A larger prospective clinical trial is justified based on encouraging results of this pilot study.

Keywords: diabetic retinopathy • edema • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×